权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Somatostatin receptors in the diagnosis and treatment of thyroid cancer

生长抑素受体在甲状腺癌诊断和治疗中的作用

基本信息

批准号：
10011325
负责人：
Joanna Klubo-Gwiezdzinska
金额：
$ 20.91万
依托单位：
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10011325
关键词：
Cancer Patient Cancer cell line Case Series Data Diagnosis Diagnostic Imaging Disseminated Malignant Neoplasm Enrollment Epigenetic Process Human Image Immunocompromised Host In Vitro Injections Malignant - descriptor Malignant neoplasm of thyroid Metastatic Neoplasm to the Liver Metastatic Neoplasm to the Lung Modeling Mus Neoplasm Metastasis Neuroendocrine Tumors PET/CT scan Papillary Papillary thyroid carcinoma Patients Pharmacology Phase II Clinical Trials RNA analysis Radioactive Iodine Radiolabeled Refractory Regimen SSTR2 gene Sampling Somatostatin Receptor Stains Tail Testing The Cancer Genome Atlas Therapeutic Thyroid Gland Thyroid Nodule Thyroidectomy Tissue Sample Tissues Treatment Efficacy United States National Institutes of Health Veins X-Ray Computed Tomography analog base cancer cell epigenetic regulation human model in vitro Model in vivo Model medullary thyroid carcinoma molecular targeted therapies mouse model overexpression radioiodine therapy somatostatin receptor 2 transcriptome sequencing tumor uptake

项目摘要

We documented somatostatin receptors type 2 (SSTR2) expression in thyroid cancer by the analysis of RNA seq data of 507 patients with papillary thyroid cancer enrolled in Thyroid Cancer Genome Atlas (TCGA) and showed higher expression of SSTR2 in tumor vs normal thyroid tissue (p=0.03). Immunohistochemical staining of 64 thyroid cancer tissue samples revealed high SSTR2 expression in 61% of thyroid cancer samples. We have utilized in vitro models of human papillary, follicular and medullary thyroid cancer and documented a moderate expression of SSTR2 in examined human thyroid cancer cell lines. We have shown that expression of SSTR2 is controlled by epigenetic mechanisms and treatment with certain pharmacological agents involved in epigenetic regulation leads to overexpression of SSTR2 in vitro. We developed a metastatic mouse model using immunocompromised mice developing lung and liver metastases after tail vein injection of human thyroid cancer cells. We showed a moderate level of radiolabeled SSTR2 analogs uptake in metastatic lesions as documented by PET/CT imaging in this model.These preliminary data indicate that (1) SSTR2 are expressed in thyroid cancer, (2) expression of SSTR2 could be increased by pharmacological agents involved in epigenetic modulation (3) SSTR2 based imaging and treatment can be tested in an established thyroid cancer metastatic mouse model that we have developed. Our preliminary results will form a basis for a phase 2 clinical trial involving 30 metastatic thyroid cancer patients, whose tumors are radioactive iodine refractory, but SSTR2 analogs-avid, utilizing the most effective therapeutic regimen from in vivo model.

我们通过分析入选甲状腺癌基因组图谱（TCGA）的507例乳头状甲状腺癌患者的RNA seq数据，记录了生长抑素受体2型（SSTR2）在甲状腺癌中的表达，发现SSTR2在肿瘤组织中的表达高于正常甲状腺组织（p=0.03）。64例甲状腺癌组织样本的免疫组化染色显示，61%的甲状腺癌样本高表达SSTR2。我们利用人乳头状癌、滤泡癌和甲状腺髓样癌的体外模型，记录了SSTR2在检查的人甲状腺癌细胞系中的适度表达。我们已经证明SSTR2的表达受表观遗传机制控制，并且通过参与表观遗传调控的某些药物治疗可导致SSTR2在体外过表达。我们建立了转移小鼠模型，使用免疫功能低下的小鼠在尾静脉注射人甲状腺癌细胞后发生肺和肝转移。我们在该模型中通过PET/CT成像显示转移性病变中有中等水平的放射性标记SSTR2类似物摄取。这些初步数据表明：(1)SSTR2在甲状腺癌中表达；(2)参与表观遗传调节的药物可以增加SSTR2的表达；(3)基于SSTR2的成像和治疗可以在我们建立的甲状腺癌转移小鼠模型中进行测试。